ArticleJournal of thoracic disease2025
The value of the monocyte to high-density lipoprotein cholesterol ratio in predicting the thrombosis burden and long-term prognosis of acute myocardial infarction patients: a retrospective cohort study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Retrospective cohort study: association of Monocyte/HDL cholesterol ratio with early mortality in patients undergoing sutureless aortic valve replacement for aortic stenosis.Journal of cardiothoracic surgery · 2026Article
- Association between the monocyte-to-high-density lipoprotein cholesterol ratio and abdominal aortic calcification in adults: Insights from the National Health and Nutrition Examination Survey (2013-2014).The Journal of international medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Percutaneous coronary intervention has an irreplaceable role in the treatment of patients with acute myocardial infarction (AMI), but it may exacerbate distal microthrombosis, lead to the further impairment of myocardial perfusion and microcirculation, and ultimately lead to a poor prognosis. Therefore, it is important to evaluate biomarkers that help estimate the thrombosis burden and long-term prognosis of AMI patients. Recent studies have found that the monocyte-to-high-density lipoprotein cholesterol ratio (MHR) is closely related to the development of cardiovascular disease. The present study aimed to investigate the value of the MHR in predicting the thrombosis burden and long-term prognosis of AMI patients. Methods: From January 2018 to December 2019, the data of 324 AMI patients who underwent percutaneous coronary intervention at Affiliated Jinhua Hospital, Zhejiang University School of Medicine were retrospectively collected. All the patients underwent percutaneous coronary intervention. The thrombosis burden of the patients was assessed by thrombolysis in myocardial infarction (TIMI) grading. The MHR of the patients on admission was detected by automatic blood routine analyzer and automatic biochemical analyzer, and the MHR was calculated. According to the median of MHR, the patients were assigned to the high MHR group (n=162), and low MHR group (n=162). The patients were followed for 5 years. The incidences of recurrent major adverse cardiovascular events (MACEs) and mortality were observed, and the relationships between the MHR, and the thrombosis burden, MACE, and mortality were analyzed. Results: Significant differences were found in the left ventricular ejection fraction (LVEF), TIMI grade, the rate of 5-year MACE, and 5-year mortality between the high and low MHR groups (P<0.05). The MHR was valuable in predicting grade 4-5 TIMI, 5-year MACE, and 5-year mortality in the AMI patients, which had areas under the curve of the receiver operating characteristic (ROC) curves of 0.776 [95% confidence interval (CI): 0.712-0.840, P<0.001], 0.743 (95% CI: 0.681-0.805, P<0.001), and 0.790 (95% CI: 0.726-0.854, P<0.001), respectively. A high MHR was an independent risk factor for grade 4-5 TIMI, the 5-year MACE rate, and 5-year mortality in AMI patients, which had relative risks of 2.367 (95% CI: 1.165-4.807), 2.259 (95% CI: 1.088-4.690), and 2.524 (95% CI: 1.214-5.245). Conclusions: The MHR can be used to predict the thrombosis burden and long-term prognosis of AMI patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.